Dr. Scholz on Using Abiraterone in mCRPC
Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the final analysis of the COU-AA-302 study, which compared abiraterone acetate to prednisone alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the final analysis of the COU-AA-302 study, which compared abiraterone acetate to prednisone alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
The COU-AA-302 study demonstrated an unequivocal survival advantage for abiraterone compared to placebo, Scholz says. This is a revolutionary development, he adds, because the standard of care for this disease has been docetaxel.
In comparing abiraterone and docetaxel, Scholz finds there is equal efficacy. However, a substantial reduction in toxicity and convenience of administration exists in using abiraterone.
Almost universally within Prostate Oncology Specialists, patients with mCRPC are being treated with abiraterone prior to docetaxel, in light of these findings.
<<<
%201%20(1)%20copy.jpg?fit=crop&auto=format)
